(Q58023977)

8

object named as

T Haferlach

0 references

Claudia Haferlach

6

object named as

C Haferlach

0 references

Susanne Schnittger

5

object named as

S Schnittger

0 references

author name string

G Metzgeroth

1

0 references

C Walz

2

0 references

J Score

3

0 references

R Siebert

4

0 references

H Popp

7

0 references

P Erben

9

0 references

J Mix

10

0 references

M C Müller

11

0 references

H Beneke

12

0 references

L Müller

13

0 references

F Del Valle

14

0 references

W E Aulitzky

15

0 references

G Wittkowsky

16

0 references

N Schmitz

17

0 references

C Schulte

18

0 references

K Müller-Hermelink

19

0 references

E Hodges

20

0 references

S J Whittaker

21

0 references

F Diecker

22

0 references

H Döhner

23

0 references

P Schuld

24

0 references

R Hehlmann

25

0 references

N C P Cross

27

0 references

A Reiter

Cytogenetic and molecular genetic aspects of eosinophilic leukaemias

28

0 references

publication date

22 March 2007

0 references

published in

Leukemia

0 references

volume

21

0 references

issue

6

0 references

page(s)

1183-1188

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Myelodysplastic syndrome with clonal eosinophilia accompanied by eosinophilic pulmonary interstitial infiltration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Modern diagnosis and treatment of primary eosinophilia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using LightCycler technology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Alternative splicing and genomic structure of theAML1gene involved in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Tyrosine kinase fusion genes in chronic myeloproliferative diseases.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404662

7 January 2021